Dishman Carbogen Amcis Limited has informed the Exchange about General Updates

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

DCAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹283.30

prior close

₹272.85

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-1.6% vs market

Pharmaceuticals peers, median of 148sector-0.5%-1.5% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+2.0

15m

+0.6

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-0.3-1.6-0.5-1.5

Next day

-3.6-0.0-3.6-0.5-3.1

-8.0-1.0-7.0-1.8-6.2

-11.4-1.3-10.1-2.6-8.8

-15.4-3.1-12.3-4.0-11.4

-14.4-2.8-11.6-3.6-10.8

-14.4-2.1-12.3-3.0-11.4

15d

-7.5+1.6-9.1-0.1-7.5

-10.9+1.4-12.3+0.3-11.2

-10.0-2.7-7.3-4.4-5.6

-5.4+0.1-5.5-3.1-2.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The company announced that the US FDA inspection at its Naroda, Ahmedabad facility was successfully completed on 12th June 2025. The inspection was concluded without any observations and no Form 483 was issued, meaning the regulator found no compliance concerns. With this, the company's facilities at Naroda and Bavla in India, along with multiple group facilities in Switzerland and the Netherlands, continue to remain US FDA approved. This is a positive regulatory outcome that supports the company's ability to serve US markets without disruption.

Likely market impact

Positive for shareholders — a clean US FDA inspection removes regulatory overhang and confirms the company can continue supplying the US market from this facility, supporting business continuity and potential new order wins.